Immune-Related Polyneuropathy and Generalized Myoclonus Associated with Pembrolizumab in a Patient with Metastatic Melanoma: A Case Report and Literature Review
Year: 2026
Type: article
Study design: Case Report
Abstract: Pembrolizumab is used to treat metastatic melanoma but may cause neurological immune-related adverse events involving the peripheral and central nervous systems. We report a 45-year-old man who developed painful sensory-motor polyneuropathy and clinically identified negative myoclonus during pembrolizumab-based treatment. Initial cerebrospinal fluid analysis showed lymphocytic pleocytosis and elevated protein, followed by albuminocytologic dissociation on repeat sampling. Electroencephalography (EEG) was unavailable. The initial episode was classified clinically as grade 2 and improved after corticosteroids and symptomatic treatment. Following pembrolizumab reintroduction, severe neurological symptoms recurred in September 2024, with a modified Rankin Scale score of 4, leading to permanent discontinuation. An August 2025 electrophysiological report described persistent severe mixed axonal and demyelinating sensory-motor neuropathy. The patient subsequently developed systemic and brain metastatic progression and died in April 2026. The temporal course supports suspected treatment-related neurological toxicity, but incomplete etiological and electrophysiological characterization limits causal attribution, particularly for myoclonus.
Institution: Hospital de Câncer de Barretos
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: Hospital de Câncer de Barretos
OpenAlex ID: W7236713692
